TR 380 Mouse Pathology Tables
NTP STATISTICAL ANALYSIS OF PRIMARY TUMORS REPORT: PEIRPT08
LAB: Battelle Northwest EPINEPHRINE HCL DATE: 09/13/94
EXPERIMENT: 05095 TEST: 02 TIME: 01:00:16
TEST TYPE: CHRONIC CAGES FROM 0000 TO LAST CAGE PAGE: 1
CONT: N01-ES-38061 ROUTE: RESPIRATORY EXPOSURE WHOLE BODY NTP C#: 55663
PATHOLOGIST: E. GIDDENS S. EUSTIS CAS: 55-31-2
------------------------------------------------------------------------------------------------------------------------------------
REASONS FOR REMOVAL: ALL
REMOVAL DATE RANGE: ALL
TREATMENT GROUPS: INCLUDE ALL
NTP STATISTICAL ANALYSIS OF PRIMARY TUMORS REPORT: PEIRPT08
LAB: Battelle Northwest EPINEPHRINE HCL DATE: 09/13/94
EXPERIMENT: 05095 TEST: 02 TIME: 01:00:16
TEST TYPE: CHRONIC CAGES FROM 0000 TO LAST CAGE
CONT: N01-ES-38061 ROUTE: RESPIRATORY EXPOSURE WHOLE BODY NTP C#: 55663
PATHOLOGIST: E. GIDDENS S. EUSTIS CAS: 55-31-2
MICE(B6C3F1)
----------------------------
FOR ALL DOSES THE TUMOR RATES IN THE FOLLOWING TISSUES/ORGANS ARE BASED ON NUMBER OF TISSUES EXAMINED.
IN OTHER TISSUES/ORGANS, RATES ARE BASED ON NUMBER OF ANIMALS NECROPSIED.
----------------
Adrenal Gland
Bone Marrow
Brain
Epididymis
Gallbladder
Heart
Islets, Pancreatic
Kidney
Larynx
Liver
Lung
Nose
Ovary
Pancreas
Parathyroid Gland
Pituitary Gland
Preputial Gland
Prostate
Salivary Glands
Spleen
Testes
Thymus
Thyroid Gland
Urinary Bladder
NTP STATISTICAL ANALYSIS OF PRIMARY TUMORS REPORT: PEIRPT08
LAB: Battelle Northwest EPINEPHRINE HCL DATE: 09/13/94
EXPERIMENT: 05095 TEST: 02 TIME: 01:00:16
TEST TYPE: CHRONIC CAGES FROM 0000 TO LAST CAGE
CONT: N01-ES-38061 ROUTE: RESPIRATORY EXPOSURE WHOLE BODY NTP C#: 55663
PATHOLOGIST: E. GIDDENS S. EUSTIS CAS: 55-31-2
SUMMARY OF STATISTICALLY SIGNIFICANT (P<=.05) RESULTS
IN THE ANALYSIS OF THE STUDY OF EPINEPHRINE HCL
====================================================================================================
FEMALE MICE
-------------
ORGAN MORPHOLOGY
------- ------------
Lung Alveolar/Bronchiolar Adenoma
Thyroid Gland: Follicular Cell
Adenoma
Carcinoma or Adenoma
Uterus Sarcoma Stromal or Polyp Stromal
====================================================================================================
DATE: 09/13/94 EXPERIMENT: 05095 TEST: 02 PAGE 1
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1) -- EPINEPHRINE HCL
TERMINAL SACRIFICE AT 106 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | CONTROL 1.5MG/M3 3.0MG/M3 | CONTROL 1.5MG/M3 3.0MG/M3 |
| | MALE MALE MALE | FEMALE FEMALE FEMALE |
|=================================================================================================================================|
| |
|Harderian Gland |
| Adenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # | # # # |
|----------- | | |
|OVERALL (a) | 2/50 (4%) 1/50 (2%) 2/50 (4%) | 1/50 (2%) 0/50 (0%) 0/50 (0%) |
|ADJUSTED (b) | 5.5% 2.9% 5.4% | 3.1% 0.0% 0.0% |
|TERMINAL (d) | 1/33 (3%) 1/34 (3%) 1/36 (3%) | 1/32 (3%) 0/35 (0%) 0/34 (0%) |
|FIRST INCIDENCE (DAYS) | 635 741 (T) 740 | 742 (T) --- --- |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.580N P=0.490N P=0.664N | P=0.260N P=0.482N P=0.488N |
|INCIDENTAL TUMOR | P=0.507 P=0.648N P=0.580 | P=0.260N P=0.482N P=0.488N |
|LOGISTIC REGRESSION | P=0.609N P=0.507N P=0.693 | P=0.260N P=0.482N P=0.488N |
|COCHRAN-ARMITAGE | P=0.610 | P=0.269N |
|FISHER EXACT | P=0.500N P=0.691N | P=0.500N P=0.500N |
|=================================================================================================================================|
| |
|Harderian Gland |
| Carcinoma or Adenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # | # # # |
|----------- | | |
|OVERALL (a) | 2/50 (4%) 2/50 (4%) 2/50 (4%) | 2/50 (4%) 0/50 (0%) 0/50 (0%) |
|ADJUSTED (b) | 5.5% 5.2% 5.4% | 6.3% 0.0% 0.0% |
|TERMINAL (d) | 1/33 (3%) 1/34 (3%) 1/36 (3%) | 2/32 (6%) 0/35 (0%) 0/34 (0%) |
|FIRST INCIDENCE (DAYS) | 635 542 740 | 742 (T) --- --- |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.579N P=0.690 P=0.664N | P=0.088N P=0.219N P=0.225N |
|INCIDENTAL TUMOR | P=0.571 P=0.689N P=0.580 | P=0.088N P=0.219N P=0.225N |
|LOGISTIC REGRESSION | P=0.600 P=0.683N P=0.693 | P=0.088N P=0.217N P=0.225N |
|COCHRAN-ARMITAGE | P=0.601 | P=0.095N |
|FISHER EXACT | P=0.691N P=0.691N | P=0.247N P=0.247N |
|=================================================================================================================================|
DATE: 09/13/94 EXPERIMENT: 05095 TEST: 02 PAGE 2
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1) -- EPINEPHRINE HCL
TERMINAL SACRIFICE AT 106 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | CONTROL 1.5MG/M3 3.0MG/M3 | CONTROL 1.5MG/M3 3.0MG/M3 |
| | MALE MALE MALE | FEMALE FEMALE FEMALE |
|=================================================================================================================================|
| |
|Liver |
| Hepatocellular Adenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 10/50 (20%) 7/25 (28%) 6/50 (12%) | 2/50 (4%) 1/20 (5%) 4/50 (8%) |
|ADJUSTED (b) | 27.7% 67.4% 13.6% | 6.3% 20.0% 11.2% |
|TERMINAL (d) | 8/33 (24%) 6/9 (67%) 2/36 (6%) | 2/32 (6%) 1/5 (20%) 3/34 (9%) |
|FIRST INCIDENCE (DAYS) | 409 456 381 | 742 (T) 742 (T) 704 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.157N P=0.094 P=0.192N | P=0.289 P=0.435 P=0.357 |
|INCIDENTAL TUMOR | P=0.086N P=0.191 P=0.054N | P=0.288 P=0.435 P=0.354 |
|LOGISTIC REGRESSION | P=0.177N P=0.160 P=0.174N | P=0.276 P=0.435 P=0.342 |
|COCHRAN-ARMITAGE | P=0.183N | P=0.261 |
|FISHER EXACT | P=0.308 P=0.207N | P=0.642 P=0.339 |
|=================================================================================================================================|
| |
|Liver |
| Hepatocellular Carcinoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 12/50 (24%) 7/25 (28%) 10/50 (20%) | 1/50 (2%) 1/20 (5%) 2/50 (4%) |
|ADJUSTED (b) | 28.7% 31.3% 23.2% | 2.3% 20.0% 5.4% |
|TERMINAL (d) | 5/33 (15%) 2/9 (22%) 4/36 (11%) | 0/32 (0%) 1/5 (20%) 1/34 (3%) |
|FIRST INCIDENCE (DAYS) | 570 465 510 | 667 742 (T) 693 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.338N P=0.521N P=0.382N | P=0.402 P=0.573 P=0.507 |
|INCIDENTAL TUMOR | P=0.497 P=0.459 P=0.546 | P=0.390 P=0.502 P=0.487 |
|LOGISTIC REGRESSION | P=0.510 P=0.538 P=0.538 | P=0.391 P=0.510 P=0.500 |
|COCHRAN-ARMITAGE | P=0.361N | P=0.390 |
|FISHER EXACT | P=0.456 P=0.405N | P=0.493 P=0.500 |
|=================================================================================================================================|
DATE: 09/13/94 EXPERIMENT: 05095 TEST: 02 PAGE 3
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1) -- EPINEPHRINE HCL
TERMINAL SACRIFICE AT 106 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | CONTROL 1.5MG/M3 3.0MG/M3 | CONTROL 1.5MG/M3 3.0MG/M3 |
| | MALE MALE MALE | FEMALE FEMALE FEMALE |
|=================================================================================================================================|
| |
|Liver |
| Hepatocellular Carcinoma or Hepatocellular Adenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 20/50 (40%) 14/25 (56%) 15/50 (30%) | 3/50 (6%) 2/20 (10%) 6/50 (12%) |
|ADJUSTED (b) | 46.5% 90.4% 32.6% | 8.4% 40.0% 16.2% |
|TERMINAL (d) | 11/33 (33%) 8/9 (89%) 6/36 (17%) | 2/32 (6%) 2/5 (40%) 4/34 (12%) |
|FIRST INCIDENCE (DAYS) | 409 456 381 | 667 742 (T) 693 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.168N P=0.191 P=0.201N | P=0.219 P=0.279 P=0.264 |
|INCIDENTAL TUMOR | P=0.198N P=0.099 P=0.159N | P=0.212 P=0.234 P=0.249 |
|LOGISTIC REGRESSION | P=0.258N P=0.098 P=0.309N | P=0.200 P=0.268 P=0.242 |
|COCHRAN-ARMITAGE | P=0.178N | P=0.193 |
|FISHER EXACT | P=0.143 P=0.201N | P=0.444 P=0.243 |
|=================================================================================================================================|
| |
|Liver |
| Hepatocellular Carcinoma, Hepatocellular Adenoma, or Hepatoblastoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 20/50 (40%) 14/25 (56%) 15/50 (30%) | 3/50 (6%) 2/20 (10%) 6/50 (12%) |
|ADJUSTED (b) | 46.5% 90.4% 32.6% | 8.4% 40.0% 16.2% |
|TERMINAL (d) | 11/33 (33%) 8/9 (89%) 6/36 (17%) | 2/32 (6%) 2/5 (40%) 4/34 (12%) |
|FIRST INCIDENCE (DAYS) | 409 456 381 | 667 742 (T) 693 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.168N P=0.191 P=0.201N | P=0.219 P=0.279 P=0.264 |
|INCIDENTAL TUMOR | P=0.198N P=0.099 P=0.159N | P=0.212 P=0.234 P=0.249 |
|LOGISTIC REGRESSION | P=0.258N P=0.098 P=0.309N | P=0.200 P=0.268 P=0.242 |
|COCHRAN-ARMITAGE | P=0.178N | P=0.193 |
|FISHER EXACT | P=0.143 P=0.201N | P=0.444 P=0.243 |
|=================================================================================================================================|
DATE: 09/13/94 EXPERIMENT: 05095 TEST: 02 PAGE 4
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1) -- EPINEPHRINE HCL
TERMINAL SACRIFICE AT 106 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | CONTROL 1.5MG/M3 3.0MG/M3 | CONTROL 1.5MG/M3 3.0MG/M3 |
| | MALE MALE MALE | FEMALE FEMALE FEMALE |
|=================================================================================================================================|
| |
|Lung |
| Alveolar/Bronchiolar Adenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 11/50 (22%) 9/32 (28%) 10/50 (20%) | 3/50 (6%) 5/27 (19%) 1/50 (2%) |
|ADJUSTED (b) | 28.1% 46.3% 26.2% | 9.4% 35.0% 2.8% |
|TERMINAL (d) | 7/33 (21%) 7/16 (44%) 8/36 (22%) | 3/32 (9%) 4/12 (33%) 0/34 (0%) |
|FIRST INCIDENCE (DAYS) | 409 456 694 | 742 (T) 693 730 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.383N P=0.311 P=0.436N | P=0.257N P=0.041 * P=0.286N |
|INCIDENTAL TUMOR | P=0.507N P=0.195 P=0.558N | P=0.270N P=0.031 * P=0.298N |
|LOGISTIC REGRESSION | P=0.462N P=0.325 P=0.507N | P=0.277N P=0.024 * P=0.296N |
|COCHRAN-ARMITAGE | P=0.453N | P=0.279N |
|FISHER EXACT | P=0.354 P=0.500N | P=0.095 P=0.309N |
|=================================================================================================================================|
| |
|Lung |
| Alveolar/Bronchiolar Carcinoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 5/50 (10%) 3/32 (9%) 6/50 (12%) | 2/50 (4%) 0/27 (0%) 1/50 (2%) |
|ADJUSTED (b) | 14.7% 14.7% 15.3% | 4.5% 0.0% 2.4% |
|TERMINAL (d) | 4/33 (12%) 2/16 (13%) 4/36 (11%) | 0/32 (0%) 0/12 (0%) 0/34 (0%) |
|FIRST INCIDENCE (DAYS) | 709 659 604 | 558 --- 685 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.488 P=0.640 P=0.552 | P=0.362N P=0.245N P=0.500N |
|INCIDENTAL TUMOR | P=0.343 P=0.640 P=0.391 | P=0.447N P=0.262N P=0.641N |
|LOGISTIC REGRESSION | P=0.436 P=0.574 P=0.497 | P=0.368N P=0.358N P=0.498N |
|COCHRAN-ARMITAGE | P=0.436 | P=0.371N |
|FISHER EXACT | P=0.621N P=0.500 | P=0.419N P=0.500N |
|=================================================================================================================================|
DATE: 09/13/94 EXPERIMENT: 05095 TEST: 02 PAGE 5
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1) -- EPINEPHRINE HCL
TERMINAL SACRIFICE AT 106 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | CONTROL 1.5MG/M3 3.0MG/M3 | CONTROL 1.5MG/M3 3.0MG/M3 |
| | MALE MALE MALE | FEMALE FEMALE FEMALE |
|=================================================================================================================================|
| |
|Lung |
| Alveolar/Bronchiolar Carcinoma or Alveolar/Bronchiolar Adenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 15/50 (30%) 11/32 (34%) 16/50 (32%) | 5/50 (10%) 5/27 (19%) 2/50 (4%) |
|ADJUSTED (b) | 38.3% 53.5% 39.8% | 13.5% 35.0% 5.1% |
|TERMINAL (d) | 10/33 (30%) 8/16 (50%) 12/36 (33%) | 3/32 (9%) 4/12 (33%) 0/34 (0%) |
|FIRST INCIDENCE (DAYS) | 409 456 604 | 558 693 685 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.530N P=0.382 P=0.576N | P=0.182N P=0.213 P=0.210N |
|INCIDENTAL TUMOR | P=0.340 P=0.273 P=0.372 | P=0.217N P=0.175 P=0.282N |
|LOGISTIC REGRESSION | P=0.444 P=0.351 P=0.488 | P=0.198N P=0.179 P=0.216N |
|COCHRAN-ARMITAGE | P=0.457 | P=0.196N |
|FISHER EXACT | P=0.429 P=0.500 | P=0.237 P=0.218N |
|=================================================================================================================================|
| |
|Mammary Gland |
| Carcinoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # | # # # |
|----------- | | |
|OVERALL (a) | 0/50 (0%) 0/50 (0%) 0/50 (0%) | 1/50 (2%) 0/50 (0%) 2/50 (4%) |
|ADJUSTED (b) | 0.0% 0.0% 0.0% | 3.1% 0.0% 5.9% |
|TERMINAL (d) | 0/33 (0%) 0/34 (0%) 0/36 (0%) | 1/32 (3%) 0/35 (0%) 2/34 (6%) |
|FIRST INCIDENCE (DAYS) | --- --- --- | 742 (T) --- 742 (T) |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | (e) (e) (e) | P=0.375 P=0.482N P=0.521 |
|INCIDENTAL TUMOR | (e) (e) (e) | P=0.375 P=0.482N P=0.521 |
|LOGISTIC REGRESSION | (e) (e) (e) | P=0.375 P=0.482N P=0.521 |
|COCHRAN-ARMITAGE | (e) | P=0.360 |
|FISHER EXACT | (e) (e) | P=0.500N P=0.500 |
|=================================================================================================================================|
DATE: 09/13/94 EXPERIMENT: 05095 TEST: 02 PAGE 6
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1) -- EPINEPHRINE HCL
TERMINAL SACRIFICE AT 106 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | CONTROL 1.5MG/M3 3.0MG/M3 | CONTROL 1.5MG/M3 3.0MG/M3 |
| | MALE MALE MALE | FEMALE FEMALE FEMALE |
|=================================================================================================================================|
| |
|Ovary |
| Cystadenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | | 3/50 (6%) 0/26 (0%) 1/50 (2%) |
|ADJUSTED (b) | | 9.4% 0.0% 2.9% |
|TERMINAL (d) | | 3/32 (9%) 0/12 (0%) 1/34 (3%) |
|FIRST INCIDENCE (DAYS) | | 742 (T) --- 742 (T) |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | | P=0.187N P=0.336N P=0.283N |
|INCIDENTAL TUMOR | | P=0.187N P=0.336N P=0.283N |
|LOGISTIC REGRESSION | | P=0.187N P=0.336N P=0.283N |
|COCHRAN-ARMITAGE | | P=0.196N |
|FISHER EXACT | | P=0.279N P=0.309N |
|=================================================================================================================================|
| |
|Pituitary Gland: Pars Distalis or Unspecified Site |
| Adenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 0/50 (0%) 0/16 (0%) 0/48 (0%) | 7/49 (14%) 11/46 (24%) 12/49 (24%) |
|ADJUSTED (b) | 0.0% 0.0% 0.0% | 21.1% 32.9% 33.5% |
|TERMINAL (d) | 0/33 (0%) 0/0 0/34 (0%) | 6/31 (19%) 10/32 (31%) 10/33 (30%) |
|FIRST INCIDENCE (DAYS) | --- --- --- | 615 661 680 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | (e) (e) (e) | P=0.159 P=0.229 P=0.186 |
|INCIDENTAL TUMOR | (e) (e) (e) | P=0.134 P=0.211 P=0.144 |
|LOGISTIC REGRESSION | (e) (e) (e) | P=0.131 P=0.163 P=0.152 |
|COCHRAN-ARMITAGE | (e) | P=0.132 |
|FISHER EXACT | (e) (e) | P=0.175 P=0.153 |
|=================================================================================================================================|
DATE: 09/13/94 EXPERIMENT: 05095 TEST: 02 PAGE 7
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1) -- EPINEPHRINE HCL
TERMINAL SACRIFICE AT 106 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | CONTROL 1.5MG/M3 3.0MG/M3 | CONTROL 1.5MG/M3 3.0MG/M3 |
| | MALE MALE MALE | FEMALE FEMALE FEMALE |
|=================================================================================================================================|
| |
|Skin: Subcutaneous Tissue |
| Hemangiosarcoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # | # # # |
|----------- | | |
|OVERALL (a) | 2/50 (4%) 0/50 (0%) 0/50 (0%) | 0/50 (0%) 2/50 (4%) 0/50 (0%) |
|ADJUSTED (b) | 5.2% 0.0% 0.0% | 0.0% 5.1% 0.0% |
|TERMINAL (d) | 0/33 (0%) 0/34 (0%) 0/36 (0%) | 0/32 (0%) 1/35 (3%) 0/34 (0%) |
|FIRST INCIDENCE (DAYS) | 635 --- --- | --- 616 --- |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.094N P=0.240N P=0.231N | P=0.659N P=0.250 (e) |
|INCIDENTAL TUMOR | P=0.202N P=0.387N P=0.409N | P=0.602 P=0.282 (e) |
|LOGISTIC REGRESSION | P=0.093N P=0.231N P=0.232N | P=0.668N P=0.234 (e) |
|COCHRAN-ARMITAGE | P=0.095N | P=0.669 |
|FISHER EXACT | P=0.247N P=0.247N | P=0.247 (e) |
|=================================================================================================================================|
| |
|Spleen |
| Hemangiosarcoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 1/50 (2%) 1/20 (5%) 3/50 (6%) | 0/50 (0%) 0/25 (0%) 1/50 (2%) |
|ADJUSTED (b) | 3.0% 25.0% 7.5% | 0.0% 0.0% 2.9% |
|TERMINAL (d) | 1/33 (3%) 1/4 (25%) 1/36 (3%) | 0/32 (0%) 0/10 (0%) 1/34 (3%) |
|FIRST INCIDENCE (DAYS) | 741 (T) 741 (T) 637 | --- --- 742 (T) |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.255 P=0.256 P=0.335 | P=0.306 (e) P=0.512 |
|INCIDENTAL TUMOR | P=0.168 P=0.256 P=0.200 | P=0.306 (e) P=0.512 |
|LOGISTIC REGRESSION | P=0.231 P=0.256 P=0.302 | P=0.306 (e) P=0.512 |
|COCHRAN-ARMITAGE | P=0.226 | P=0.287 |
|FISHER EXACT | P=0.493 P=0.309 | (e) P=0.500 |
|=================================================================================================================================|
DATE: 09/13/94 EXPERIMENT: 05095 TEST: 02 PAGE 8
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1) -- EPINEPHRINE HCL
TERMINAL SACRIFICE AT 106 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | CONTROL 1.5MG/M3 3.0MG/M3 | CONTROL 1.5MG/M3 3.0MG/M3 |
| | MALE MALE MALE | FEMALE FEMALE FEMALE |
|=================================================================================================================================|
| |
|Thyroid Gland: Follicular Cell |
| Adenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 0/49 (0%) 0/15 (0%) 1/50 (2%) | 3/49 (6%) 2/18 (11%) 1/48 (2%) |
|ADJUSTED (b) | 0.0% 0.0% 2.8% | 9.1% 66.7% 2.9% |
|TERMINAL (d) | 0/33 (0%) 0/0 1/36 (3%) | 2/32 (6%) 2/3 (67%) 1/34 (3%) |
|FIRST INCIDENCE (DAYS) | --- --- 741 (T) | 732 742 (T) 742 (T) |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.324 (e) P=0.517 | P=0.233N P=0.190 P=0.288N |
|INCIDENTAL TUMOR | P=0.324 (e) P=0.517 | P=0.241N P=0.137 P=0.298N |
|LOGISTIC REGRESSION | P=0.324 (e) P=0.517 | P=0.243N P=0.041 * P=0.295N |
|COCHRAN-ARMITAGE | P=0.298 | P=0.254N |
|FISHER EXACT | (e) P=0.505 | P=0.408 P=0.316N |
|=================================================================================================================================|
| |
|Thyroid Gland: Follicular Cell |
| Carcinoma or Adenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 0/49 (0%) 0/15 (0%) 1/50 (2%) | 3/49 (6%) 2/18 (11%) 2/48 (4%) |
|ADJUSTED (b) | 0.0% 0.0% 2.8% | 9.1% 66.7% 5.9% |
|TERMINAL (d) | 0/33 (0%) 0/0 1/36 (3%) | 2/32 (6%) 2/3 (67%) 2/34 (6%) |
|FIRST INCIDENCE (DAYS) | --- --- 741 (T) | 732 742 (T) 742 (T) |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.324 (e) P=0.517 | P=0.390N P=0.190 P=0.475N |
|INCIDENTAL TUMOR | P=0.324 (e) P=0.517 | P=0.397N P=0.137 P=0.486N |
|LOGISTIC REGRESSION | P=0.324 (e) P=0.517 | P=0.400N P=0.041 * P=0.487N |
|COCHRAN-ARMITAGE | P=0.298 | P=0.426N |
|FISHER EXACT | (e) P=0.505 | P=0.408 P=0.510N |
|=================================================================================================================================|
DATE: 09/13/94 EXPERIMENT: 05095 TEST: 02 PAGE 9
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1) -- EPINEPHRINE HCL
TERMINAL SACRIFICE AT 106 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | CONTROL 1.5MG/M3 3.0MG/M3 | CONTROL 1.5MG/M3 3.0MG/M3 |
| | MALE MALE MALE | FEMALE FEMALE FEMALE |
|=================================================================================================================================|
| |
|Uterus |
| Carcinoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | # # # |
|----------- | | |
|OVERALL (a) | | 0/50 (0%) 1/50 (2%) 2/50 (4%) |
|ADJUSTED (b) | | 0.0% 2.9% 5.9% |
|TERMINAL (d) | | 0/32 (0%) 1/35 (3%) 2/34 (6%) |
|FIRST INCIDENCE (DAYS) | | --- 742 (T) 742 (T) |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | | P=0.149 P=0.518 P=0.252 |
|INCIDENTAL TUMOR | | P=0.149 P=0.518 P=0.252 |
|LOGISTIC REGRESSION | | P=0.149 P=0.518 P=0.252 |
|COCHRAN-ARMITAGE | | P=0.142 |
|FISHER EXACT | | P=0.500 P=0.247 |
|=================================================================================================================================|
| |
|Uterus |
| Polyp Stromal |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | # # # |
|----------- | | |
|OVERALL (a) | | 0/50 (0%) 1/50 (2%) 3/50 (6%) |
|ADJUSTED (b) | | 0.0% 2.9% 8.5% |
|TERMINAL (d) | | 0/32 (0%) 1/35 (3%) 2/34 (6%) |
|FIRST INCIDENCE (DAYS) | | --- 742 (T) 730 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | | P=0.066 P=0.518 P=0.134 |
|INCIDENTAL TUMOR | | P=0.066 P=0.518 P=0.125 |
|LOGISTIC REGRESSION | | P=0.062 P=0.518 P=0.123 |
|COCHRAN-ARMITAGE | | P=0.060 |
|FISHER EXACT | | P=0.500 P=0.121 |
|=================================================================================================================================|
DATE: 09/13/94 EXPERIMENT: 05095 TEST: 02 PAGE 10
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1) -- EPINEPHRINE HCL
TERMINAL SACRIFICE AT 106 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | CONTROL 1.5MG/M3 3.0MG/M3 | CONTROL 1.5MG/M3 3.0MG/M3 |
| | MALE MALE MALE | FEMALE FEMALE FEMALE |
|=================================================================================================================================|
| |
|Uterus |
| Sarcoma Stromal or Polyp Stromal |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | # # # |
|----------- | | |
|OVERALL (a) | | 0/50 (0%) 1/50 (2%) 4/50 (8%) |
|ADJUSTED (b) | | 0.0% 2.9% 11.1% |
|TERMINAL (d) | | 0/32 (0%) 1/35 (3%) 2/34 (6%) |
|FIRST INCIDENCE (DAYS) | | --- 742 (T) 730 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | | P=0.029 * P=0.518 P=0.073 |
|INCIDENTAL TUMOR | | P=0.029 * P=0.518 P=0.062 |
|LOGISTIC REGRESSION | | P=0.027 * P=0.518 P=0.064 |
|COCHRAN-ARMITAGE | | P=0.026 * |
|FISHER EXACT | | P=0.500 P=0.059 |
|=================================================================================================================================|
| |
|All Organs |
| Hemangioma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # | # # # |
|----------- | | |
|OVERALL (a) | 1/50 (2%) 0/50 (0%) 1/50 (2%) | 2/50 (4%) 1/50 (2%) 0/50 (0%) |
|ADJUSTED (b) | 2.4% 0.0% 2.8% | 6.3% 2.9% 0.0% |
|TERMINAL (d) | 0/33 (0%) 0/34 (0%) 1/36 (3%) | 2/32 (6%) 1/35 (3%) 0/34 (0%) |
|FIRST INCIDENCE (DAYS) | 610 --- 741 (T) | 742 (T) 742 (T) --- |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.661N P=0.505N P=0.753N | P=0.130N P=0.469N P=0.225N |
|INCIDENTAL TUMOR | P=0.535 P=0.795N P=0.659 | P=0.130N P=0.469N P=0.225N |
|LOGISTIC REGRESSION | P=0.667N P=0.469N P=0.760N | P=0.130N P=0.469N P=0.225N |
|COCHRAN-ARMITAGE | P=0.669N | P=0.142N |
|FISHER EXACT | P=0.500N P=0.753N | P=0.500N P=0.247N |
|=================================================================================================================================|
DATE: 09/13/94 EXPERIMENT: 05095 TEST: 02 PAGE 11
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1) -- EPINEPHRINE HCL
TERMINAL SACRIFICE AT 106 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | CONTROL 1.5MG/M3 3.0MG/M3 | CONTROL 1.5MG/M3 3.0MG/M3 |
| | MALE MALE MALE | FEMALE FEMALE FEMALE |
|=================================================================================================================================|
| |
|All Organs |
| Hemangiosarcoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # | # # # |
|----------- | | |
|OVERALL (a) | 4/50 (8%) 2/50 (4%) 4/50 (8%) | 2/50 (4%) 2/50 (4%) 2/50 (4%) |
|ADJUSTED (b) | 11.0% 5.9% 10.2% | 4.6% 5.1% 5.9% |
|TERMINAL (d) | 2/33 (6%) 2/34 (6%) 2/36 (6%) | 0/32 (0%) 1/35 (3%) 2/34 (6%) |
|FIRST INCIDENCE (DAYS) | 635 741 (T) 637 | 615 616 742 (T) |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.540N P=0.330N P=0.602N | P=0.586N P=0.690N P=0.681N |
|INCIDENTAL TUMOR | P=0.431 P=0.428N P=0.466 | P=0.506 P=0.689N P=0.606 |
|LOGISTIC REGRESSION | P=0.576 P=0.349N P=0.427 | P=0.600N P=0.685 P=0.695N |
|COCHRAN-ARMITAGE | P=0.579 | P=0.601 |
|FISHER EXACT | P=0.339N P=0.643N | P=0.691N P=0.691N |
|=================================================================================================================================|
| |
|All Organs |
| Hemangiosarcoma or Hemangioma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # | # # # |
|----------- | | |
|OVERALL (a) | 5/50 (10%) 2/50 (4%) 5/50 (10%) | 4/50 (8%) 3/50 (6%) 2/50 (4%) |
|ADJUSTED (b) | 13.1% 5.9% 12.8% | 10.5% 7.9% 5.9% |
|TERMINAL (d) | 2/33 (6%) 2/34 (6%) 3/36 (8%) | 2/32 (6%) 2/35 (6%) 2/34 (6%) |
|FIRST INCIDENCE (DAYS) | 610 741 (T) 637 | 615 616 742 (T) |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.534N P=0.217N P=0.588N | P=0.249N P=0.478N P=0.321N |
|INCIDENTAL TUMOR | P=0.379 P=0.373N P=0.406 | P=0.318N P=0.468N P=0.403N |
|LOGISTIC REGRESSION | P=0.413 P=0.223N P=0.371 | P=0.264N P=0.501N P=0.337N |
|COCHRAN-ARMITAGE | P=0.573 | P=0.264N |
|FISHER EXACT | P=0.218N P=0.630N | P=0.500N P=0.339N |
|=================================================================================================================================|
DATE: 09/13/94 EXPERIMENT: 05095 TEST: 02 PAGE 12
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1) -- EPINEPHRINE HCL
TERMINAL SACRIFICE AT 106 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | CONTROL 1.5MG/M3 3.0MG/M3 | CONTROL 1.5MG/M3 3.0MG/M3 |
| | MALE MALE MALE | FEMALE FEMALE FEMALE |
|=================================================================================================================================|
| |
|All Organs |
| Malignant Lymphoma And Histiocytic Sarcoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # | # # # |
|----------- | | |
|OVERALL (a) | 9/50 (18%) 6/50 (12%) 5/50 (10%) | 17/50 (34%) 19/50 (38%) 14/50 (28%) |
|ADJUSTED (b) | 22.7% 16.4% 13.9% | 40.8% 44.7% 31.9% |
|TERMINAL (d) | 4/33 (12%) 4/34 (12%) 5/36 (14%) | 8/32 (25%) 12/35 (34%) 6/34 (18%) |
|FIRST INCIDENCE (DAYS) | 551 654 741 (T) | 503 504 421 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.133N P=0.300N P=0.171N | P=0.288N P=0.479 P=0.328N |
|INCIDENTAL TUMOR | P=0.236N P=0.401N P=0.299N | P=0.321N P=0.350 P=0.363N |
|LOGISTIC REGRESSION | P=0.155N P=0.299N P=0.198N | P=0.352N P=0.419 P=0.396N |
|COCHRAN-ARMITAGE | P=0.152N | P=0.298N |
|FISHER EXACT | P=0.288N P=0.194N | P=0.418 P=0.333N |
|=================================================================================================================================|
| |
|All Organs |
| Malignant Lymphoma: Histiocytic, Lymphocytic, Mixed, |
| NOS, or Undifferentiated Cell Type |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # | # # # |
|----------- | | |
|OVERALL (a) | 8/50 (16%) 6/50 (12%) 5/50 (10%) | 16/50 (32%) 19/50 (38%) 14/50 (28%) |
|ADJUSTED (b) | 21.1% 16.4% 13.9% | 39.3% 44.7% 31.9% |
|TERMINAL (d) | 4/33 (12%) 4/34 (12%) 5/36 (14%) | 8/32 (25%) 12/35 (34%) 6/34 (18%) |
|FIRST INCIDENCE (DAYS) | 573 654 741 (T) | 503 504 421 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.194N P=0.388N P=0.238N | P=0.352N P=0.408 P=0.395N |
|INCIDENTAL TUMOR | P=0.287N P=0.442N P=0.348N | P=0.401N P=0.293 P=0.448N |
|LOGISTIC REGRESSION | P=0.226N P=0.405N P=0.276N | P=0.434N P=0.339 P=0.482N |
|COCHRAN-ARMITAGE | P=0.226N | P=0.375N |
|FISHER EXACT | P=0.387N P=0.277N | P=0.338 P=0.414N |
|=================================================================================================================================|
DATE: 09/13/94 EXPERIMENT: 05095 TEST: 02 PAGE 13
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1) -- EPINEPHRINE HCL
TERMINAL SACRIFICE AT 106 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | CONTROL 1.5MG/M3 3.0MG/M3 | CONTROL 1.5MG/M3 3.0MG/M3 |
| | MALE MALE MALE | FEMALE FEMALE FEMALE |
|=================================================================================================================================|
| |
|All Organs |
| Benign Tumors |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # | # # # |
|----------- | | |
|OVERALL (a) | 20/50 (40%) 17/50 (34%) 19/50 (38%) | 19/50 (38%) 19/50 (38%) 19/50 (38%) |
|ADJUSTED (b) | 50.0% 46.6% 44.5% | 53.6% 49.5% 49.6% |
|TERMINAL (d) | 14/33 (42%) 15/34 (44%) 13/36 (36%) | 16/32 (50%) 16/35 (46%) 15/34 (44%) |
|FIRST INCIDENCE (DAYS) | 409 456 381 | 324 607 680 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.372N P=0.320N P=0.418N | P=0.461N P=0.466N P=0.502N |
|INCIDENTAL TUMOR | P=0.473N P=0.434N P=0.437N | P=0.525N P=0.580 P=0.565N |
|LOGISTIC REGRESSION | P=0.469N P=0.369N P=0.497N | P=0.542N P=0.576 P=0.582 |
|COCHRAN-ARMITAGE | P=0.459N | P=0.541 |
|FISHER EXACT | P=0.339N P=0.500N | P=0.582N P=0.582N |
|=================================================================================================================================|
| |
|All Organs |
| Malignant Tumors |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # | # # # |
|----------- | | |
|OVERALL (a) | 25/50 (50%) 21/50 (42%) 20/50 (40%) | 25/50 (50%) 27/50 (54%) 23/50 (46%) |
|ADJUSTED (b) | 55.0% 47.6% 45.2% | 55.1% 58.1% 51.6% |
|TERMINAL (d) | 13/33 (39%) 11/34 (32%) 12/36 (33%) | 12/32 (38%) 16/35 (46%) 13/34 (38%) |
|FIRST INCIDENCE (DAYS) | 551 465 510 | 503 384 421 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.177N P=0.316N P=0.199N | P=0.356N P=0.500 P=0.391N |
|INCIDENTAL TUMOR | P=0.471N P=0.511N P=0.543N | P=0.402N P=0.490 P=0.488N |
|LOGISTIC REGRESSION | P=0.434N P=0.464N P=0.464N | P=0.424N P=0.544 P=0.522N |
|COCHRAN-ARMITAGE | P=0.182N | P=0.382N |
|FISHER EXACT | P=0.274N P=0.211N | P=0.421 P=0.421N |
|=================================================================================================================================|
DATE: 09/13/94 EXPERIMENT: 05095 TEST: 02 PAGE 14
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN MICE(B6C3F1) -- EPINEPHRINE HCL
TERMINAL SACRIFICE AT 106 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | CONTROL 1.5MG/M3 3.0MG/M3 | CONTROL 1.5MG/M3 3.0MG/M3 |
| | MALE MALE MALE | FEMALE FEMALE FEMALE |
|=================================================================================================================================|
| |
|All Organs |
| Malignant and Benign Tumors |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # | # # # |
|----------- | | |
|OVERALL (a) | 38/50 (76%) 33/50 (66%) 33/50 (66%) | 36/50 (72%) 36/50 (72%) 30/50 (60%) |
|ADJUSTED (b) | 79.0% 73.3% 70.1% | 78.0% 76.3% 66.4% |
|TERMINAL (d) | 23/33 (70%) 22/34 (65%) 22/36 (61%) | 22/32 (69%) 24/35 (69%) 19/34 (56%) |
|FIRST INCIDENCE (DAYS) | 409 456 381 | 324 384 421 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.157N P=0.256N P=0.182N | P=0.141N P=0.449N P=0.164N |
|INCIDENTAL TUMOR | P=0.304N P=0.312N P=0.287N | P=0.123N P=0.516N P=0.163N |
|LOGISTIC REGRESSION | P=0.310N P=0.253N P=0.365N | P=0.122N P=0.587 P=0.145N |
|COCHRAN-ARMITAGE | P=0.165N | P=0.119N |
|FISHER EXACT | P=0.189N P=0.189N | P=0.588N P=0.146N |
|=================================================================================================================================|
(a) Number of tumor-bearing animals / number of animals examined at site.
(b) Kaplan-Meier estimated lifetime tumor incidence after adjustment for
intercurrent mortality.
(d) Observed incidence at terminal kill.
(f) Beneath the control incidence are the P-values associated with the trend
test. Beneath the dosed group incidence are the P-values corresponding to
pairwise comparisons between the controls and that dosed group. The life
table analysis regards tumors in animals dying prior to terminal kill as
being (directly or indirectly) the cause of death. The incidental tumor
test regards these lesions as non-fatal. Logistic regression is an alternative
method for analyzing the incidence of non-fatal tumors. The Cochran-Armitage
and Fisher's exact tests compare directly the overall incidence rates.
For all tests, a negative trend is indicated by "N".
(e) Value of Statistic cannot be computed.
(I) Interim sacrifice
(T) Terminal sacrifice
# Tumor rates based on number of animals necropsied.
* To the right of any statistical result, indicates significance at (P<=0.05).
** To the right of any statistical result, indicates significance at (P<=0.01).
--multipart-boundary
Content-type: text/plain
Range: bytes 98309-98309/98309
--multipart-boundary--